NEW YORK ( TheStreet) -- Exactech (Nasdaq: EXAC) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and a generally disappointing performance in the stock itself.

Highlights from the ratings report include:
  • EXAC's revenue growth has slightly outpaced the industry average of 6.6%. Since the same quarter one year prior, revenues slightly increased by 8.6%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • Despite currently having a low debt-to-equity ratio of 0.31, it is higher than that of the industry average, inferring that management of debt levels may need to be evaluated further. Despite the fact that EXAC's debt-to-equity ratio is mixed in its results, the company's quick ratio of 1.78 is high and demonstrates strong liquidity.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Health Care Equipment & Supplies industry. The net income has decreased by 9.0% when compared to the same quarter one year ago, dropping from $2.99 million to $2.72 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. In comparison to the other companies in the Health Care Equipment & Supplies industry and the overall market, EXACTECH INC's return on equity is significantly below that of the industry average and is below that of the S&P 500.

Exactech, Inc. develops, manufactures, markets, distributes, and sells orthopedic implant devices and related surgical instrumentation, as well as offers biologic services to hospitals and physicians in the United States and internationally. The company has a P/E ratio of 18.8, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Exactech has a market cap of $184.8 million and is part of the health care sector and health services industry. Shares are down 25.1% year to date as of the close of trading on Monday.

You can view the full Exactech Ratings Report or get investment ideas from our investment research center.
null

If you liked this article you might like

This Little-Known Orthopedic-Device Stock Is Delivering Huge Returns

Insider Trading Alert - AGNC, EXAC And TRC Traded By Insiders

Insider Trading Alert - EXAC, FORM And FIX Traded By Insiders

Insider Trading Alert - DGICA, MEET And EXAC Traded By Insiders

Will A Positive Earnings Report Help Exactech (EXAC) Stock?